- |||||||||| Trial completion, Enrollment change: Threshold Suspend in Pediatrics at Home (clinicaltrials.gov) - Jun 20, 2017
P=N/A, N=201, Completed, Active, not recruiting --> Completed | N=300 --> 201
- |||||||||| lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
Enrollment closed, Trial primary completion date: Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate (clinicaltrials.gov) - Jun 19, 2017 P2, N=83, Active, not recruiting, N=110 --> 80 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Aug 2017
- |||||||||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment closed, Enrollment change, Real-world evidence, Real-world: PROTRACT: Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® (clinicaltrials.gov) - Jun 16, 2017 P=N/A, N=479, Active, not recruiting, Recruiting --> Completed | N=400 --> 203 | Trial primary completion date: Sep 2017 --> Apr 2017 Recruiting --> Active, not recruiting | N=1000 --> 479
- |||||||||| Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Trial primary completion date: An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA (clinicaltrials.gov) - Jun 14, 2017 P=N/A, N=950, Recruiting, Active, not recruiting --> Terminated | Trial primary completion date: Aug 2017 --> May 2017 Trial primary completion date: Sep 2017 --> Dec 2019
- |||||||||| Zeposia (ozanimod) / BMS
Enrollment closed, Enrollment change, Trial primary completion date: Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS (clinicaltrials.gov) - Jun 14, 2017 P1, N=6, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=24 --> 6 | Trial primary completion date: Mar 2017 --> Dec 2017
- |||||||||| Trial completion, Enrollment change: Type One Diabetes and Low Carb Study (clinicaltrials.gov) - Jun 9, 2017
P=N/A, N=340, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Dec 2019 Recruiting --> Completed | N=500 --> 340
- |||||||||| Enrollment open: Parents of Young Adults With Type 1 Diabetes: An Exploratory Study (clinicaltrials.gov) - Jun 7, 2017
P=N/A, N=30, Recruiting, Not yet recruiting --> Recruiting | Phase classification: P1 --> P | Initiation date: Sep 2016 --> Mar 2017 | Trial primary completion date: Feb 2017 --> Jul 2018 Not yet recruiting --> Recruiting
- |||||||||| Enrollment closed, Trial primary completion date: Open-label Study of Liothyronine in MS (clinicaltrials.gov) - Jun 5, 2017
P1b, N=20, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Aug 2017
- |||||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed, Observational data, HEOR: An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice (clinicaltrials.gov) - Jun 5, 2017 P=N/A, N=120, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Aug 2017 Recruiting --> Active, not recruiting
- |||||||||| mavrilimumab (KPL-301) / Kiniksa
Trial initiation date, Trial termination: A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 1, 2017 P2, N=409, Terminated, Recruiting --> Completed Initiation date: Dec 2002 --> Jan 2013 | Completed --> Terminated; The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations.
- |||||||||| Adcetris (brentuximab vedotin) / Seagen, Takeda
Enrollment closed, Trial primary completion date: Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus (clinicaltrials.gov) - Jun 1, 2017 P2, N=40, Active, not recruiting, Initiation date: Dec 2002 --> Jan 2013 | Completed --> Terminated; The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations. Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Nov 2018
- |||||||||| Byetta (exenatide) / AstraZeneca
Enrollment open, Trial initiation date: Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes (clinicaltrials.gov) - May 31, 2017 P2/3, N=15, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2017
|